ISSN: 2249–9504
CAS CODEN: IJPCDX

STABILITY INDICATING RP-HPLC METHOD FOR SIMVASTATIN AND SITAGLIPTIN PHOSPHATE WITH DEGRADATION STUDIES IN MARKETED PHARMACEUTICAL HYPO-CHOLESTEROL AND ANTIDIABETIC TABLETS

Abstract

Author(s): Shraddha S Ghodke

Simvastatin is drug used with Sitagliptin Phosphate for a type 2 diabetes treatment. Simvastatin officially got approval from Merck in 1991 which emphasized its mechanism of action as HMGCoA reductase inhibitor which is useful in reducing cholesterol levels in the body. However Sitagliptin Phosphate works as peptidase inhibitor. Thus Juvisync which was launched into the pharmaceutical market as solid dosage forms of simvastatin and Sitagliptin Phosphate specifically tablets gained popularity due to its dual functional medicinal activity. The combination is useful due to its synergistic effect in the patients for diabetes as well as high cholesterol levels. The proposed method is developed and validated for these tablets using Reverse phase HPLC by photo diode array detector. The method also indicates stability testing by forced stress degradation studies. Drug discovery and drug development involves essential stage of stability testing during periodic studies of pharmaceutical preparations thus utilizing advanced Pharmaceutical techniques such as stress degradation sheds light on efficacy and safety of proposed and synthesized medicine

Get the App